Phase 1b/2 Study of U3-1287 in Combination With Trastuzumab Plus Paclitaxel in Newly Diagnosed Metastatic Breast Cancer (MBC)
by on Thursday, January 19th, 2012 | No Comments
Condition: Metastatic Breast Cancer
Interventions: Drug: U3-1287; Drug: Trastuzumab; Drug: Paclitaxel; Drug: U3-1287; Drug: Trastuzumab; Drug: Paclitaxel; Drug: Placebo
Sponsors: Daiichi Sankyo Inc.; ACTIVA
Recruiting – verified January 2012
Continue reading here: Phase 1b/2 Study of U3-1287 in Combination With Trastuzumab Plus Paclitaxel in Newly Diagnosed Metastatic Breast Cancer (MBC)